Drug prices come under fire as US pharma lobby nears spending records
More ambitious changes may be needed to lower pharmaceutical prices as the Trump administration proposes new rules and approves a slew of new generic drugs.
List view / Grid view
More ambitious changes may be needed to lower pharmaceutical prices as the Trump administration proposes new rules and approves a slew of new generic drugs.
Executives blamed high drug prices on the drugmakers and their pursuit of profits...
The Food and Drug Administration has released a list of 40 drugs used to treat hypertension and heart failure that don’t contain any known carcinogens...
Disposable injectors are the most commonly available type of injectors since they are user friendly and do not require special skills for administration...
The FDA has prioritised the review of this drug application after multiple recalls of generic valsartan products from several manufacturers...
The generic version will cost 50 percent less that the current Humalog list price...
The pharmaceutical drug delivery market could reach $1,694.7 billion by 2023, increasing at a CAGR of 6.4 percent during the period...
The CMA provisionally finds Auden Mckenzie and Waymade broke the law by agreeing not to compete for the supply of hydrocortisone tablets to the NHS...
Campaigners call for UK Government to intervene on pricing dispute over cystic fibrosis drug Orkambi...
Results did not confirm the clinical benefit of Lartruvo in combination with doxorubicin compared to doxorubicin alone…
A generic version of the seizure drug Sabril (vigabatrin) has been approved by the FDA...
Chairman of the Committee on Oversight and Reform sends detailed requests to 12 pharmaceutical companies about increasing drug prices...
Medical marketing increased substantially from 1997 through 2016, especially direct-to-consumer advertising for drugs and health services…
The pharma corridor between Hong Kong and Brussels Airport assures handling quality for temperature-sensitive pharmaceuticals.
The rising costs of brand-name drugs is largely driven by inflation in the prices of widely used existing drugs, according to a study published in the January issue of Health Affairs...